Mali Lab Pan-Druggable Cancer Library
(Pooled Library #182133)

• Purpose:

  This library provides an all-in-one CRISPR/Cas system composed of 74 elements: 63 sgRNAs targeting cancer-related genes with FDA-approved drug treatments, 3 sgRNAs targeting key medulloblastoma driver genes, 4 sgRNAs targeting the AAVS1 locus, and 4 non-targeting controls.

• Vector Backbone:

  The LentiCRISPR v2-GFP backbone was prepared by replacing the puromycin-resistance domain from LentiCRISPR v2 with an EGFP reporter sequence.

• Depositing Labs: Prashant Mali
• Publication: Hu et al. Biomaterials. 2022 Jan;280:121276. doi: 10.1016/j.biomaterials.2021.121276.

Library Details

• Species: Human
• Genes targeted: 66
• gRNAs: 74
• Controls: 4 sgRNAs targeting the AAVS1 locus, 4 non-targeting controls
• Lentiviral Generation: 3rd

Library Shipping

This library is delivered as suspended DNA in a microcentrifuge tube on blue ice. The tube's contents will not necessarily be frozen. For best results, minimize freeze/thaws.

• Volume: ∼20 µL
• Concentration: 50 ng/µL

Resource Information

• Protocols:
  • Library Amplification Protocol (PDF, 89 KB)
  • PCR Protocol for Illumina Sequencing Preparation (PDF, 76 KB)
• Depositor Data:
  • List of Targeted Genes and gRNA Sequences (CSV, 2.3 KB)
  • List of NGS Read Counts (CSV, 1.1 KB)
  • Sequence of LentiCRISPR v2-GFP Vector Backbone (GB, 23 KB)

Terms and Licenses

Academic/Nonprofit Terms:

• UBMTA

Industry Terms:

• Not Available to Industry

Trademarks:

• Zeocin® is an InvivoGen trademark.

Depositor Comments

Figure 1: Pan-Druggable Cancer Library design. Left: Library was designed by compiling a list of FDA-Approved cancer drugs, listing the proteins targeted by these drugs, then designing sgRNAs targeting these genes. Right: List of targeted genes, with genes associated as medulloblastoma drivers highlighted in blue. Figure adapted from Hu et al. 2022.

The depositing lab recommends using MAGeCK/MAGeCK-VISPR algorithms for analysis.